天美传媒

Landon Westfall, Ph.D., is a bacteriologist, virologist, immunologist and molecular biologist with 15 years of experience in researching medically-relevant pathogens at both pre-clinical and clinical levels. As associate director of Influenza, he is responsible for overseeing the influenza virology program, both in vitro and in vivo, at Southern Research. He leads the support effort for pre-clinical studies and clinical sample testing by designing and executing validations or qualifications for immunogenicity assays, and managing sample analysis in partnership with both commercial and government clients. In addition, Westfall has experience conducting GLP regulated general safety toxicology studies for newly discovered influenza vaccines in support of regulatory submissions to the FDA.

Prior to joining Southern Research in 2015, Westfall was principal investigator and study director at Lovelace Respiratory Research Institute, a BSL3+/ABSL3+ contract research organization, where he successfully conducted a GLP-compliant animal model qualification for an aerosolized Tier-1 Select Agent in nonhuman primates. He supervised and performed a broad range of procedures using novel and standard techniques and methods, including refining a number of animal models using both viral and bacterial species. Viral animal models were primarily mouse and ferret influenza models using seasonal, pandemic and highly pathogenic avian influenza strains. Influenza studies included testing new vaccine platforms and antivirals for efficacy on newly emerged and pandemic influenza strains.

Westfall is a member of the American Society of Microbiology. He earned his doctorate in medical microbiology from Texas Tech University (TTU) Health Sciences Center and his Bachelor of Science in biology from TTU.

Dr. Jan D. Hirsch is Founding Dean of the University of California Irvine School of Pharmacy and Pharmaceutical Sciences and also Professor of Clinical Pharmacy. She is a Distinguished Scholar and Fellow of the National Academies of Practice (NAP) in Pharmacy, and Distinguished Fellow of the Get the Medications Right (GTMRx) Institute, and joined UC Irvine in January of 2019.
Previously she was Professor of Clinical Pharmacy and Chair of the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. She was also Executive Director of an outreach program of the school providing medication therapy management services in the community. She received her B.S. in Pharmacy and M.S. and Ph.D. degrees in Pharmacy Administration from the University of South Carolina, College of Pharmacy. Prior to returning to academia, she spent 14 years in the pharmaceutical and managed care industries where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies (Glaxo Group Research in Greenford (UK) and Allergan (US)) and a pharmacy benefit management company (Prescription Solutions (US)).

Dr. Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, i) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals and ii) integrating patient reported outcomes (PRO's) [e.g. Health Related Quality of Life (HRQOL)] into pharmaceutical and medical practice to improve patient management.

She has served as PI or Co-PI for many studies evaluating the clinical, economic and humanistic outcomes for patients receiving novel pharmacy services for diabetes, hypertension, mental health, and HIV/AIDS. This research has been recognized by state and federal agencies, professional pharmacy organizations and the interdisciplinary National Academies of Practice. Dr. Hirsch has also been the PI for studies creating and/or validating four HRQOL instruments [Functional Living Index Emesis (FLIE), Ocular Surface Disease Index (OSDI), Gout Impact Scale (GIS), Heart Transplant Treatment Burden Questionnaire (HTBQ)] and a method for measuring medication regimen complexity (MRCI). Each of these has been an important contribution to clinical practice and research as evidenced by their uptake by other researchers and inclusion in more than 100 clinical trials.

Patricia LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University鈥檚 Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

An international leader in the clinical care of patients with breast cancer, Dr. Krop joined Yale from Dana-Farber Cancer Institute where he was the Associate Chief of the Division of Breast Oncology and an Associate Professor of Medicine at Harvard Medical School. Nationally, he serves as Chief Scientific Officer for the Translational Breast Cancer Research Consortium and the Co-Vice Chair for Correlative Science for the Alliance for Clinical Trials in Oncology. His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

Education & Training:
PhD-Johns Hopkins University School of Medicine, Biochemistry, Cellular and Molecular Biology
MD-The Johns Hopkins University School of Medicine, Medicine

I am Professor and Chair of the Department of Molecular and Cellular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina, Charleston, South Carolina. I am also the John C. West Chair in Cancer Research and Director of the Developmental Cancer Therapeutics Program at the Hollings Cancer Center.
I received a B.Sc. in microbiology/genetics from the University of Wales, Swansea, UK; a PhD in biochemical pharmacology; and a DSc. from the University of London. My past research and teaching positions include Georgetown University School of Medicine, Lombardi Cancer Center, Fox Chase Cancer Center, and the University of Pennsylvania.
I have served on numerous peer review committees and scientific advisory boards in the United States, Canada, Italy, UK, and United Arab Emirates.
I am currently serving as chair of ASPET’s Publication Committee. I previously served as editor in chief for the Journal of Pharmacology and Experimental Therapeutics and associate editor for Molecular Pharmacology, as well as held several other roles with editorial boards of many other journals.
 
My primary research interests include anticancer drug discovery/development and drug target identification, mechanisms of redox stress response, glutathione metabolism, and mechanisms of drug resistance. I have published over 170 research articles; 130 editorials, reviews, and book chapters; and two books. Additionally, I served as an editor on nearly 20 books and hold a number of patents.